Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GuideAI Health's revenue for the
three
months ended in Mar. 2026 was €0.00 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.
GuideAI Health's Revenue per Share for the
three
months ended in Mar. 2026 was €0.00.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
GuideAI Health Revenue Related Terms
GuideAI Health Revenue Historical Data
* Premium members only.
The historical data trend for GuideAI Health's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuideAI Health Revenue Chart
GuideAI Health Annual Data
Trend
Jun23
Jun24
Jun25
Revenue
0.00
0.00
0.00
GuideAI Health Quarterly Data
Jun23
Jun24
Mar25
Jun25
Mar26
Revenue
0.00
0.00
0.00
0.00
0.00
FRA:ZN0 vs VEEV, BTSG, TEM: Revenue Comparison
For the Health Information Services subindustry, GuideAI Health's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GuideAI Health Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, GuideAI Health's Revenue distribution charts can be found below:
* The bar in red indicates where GuideAI Health's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GuideAI Health (FRA:ZN0) has a Revenue of €0.00 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on GuideAI Health and its competitors.
Is GuideAI Health's Revenue too high?
GuideAI Health's current Revenue is €0.00 Mil. Overall, GuideAI Health has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does GuideAI Health's Revenue compare to VEEV and BTSG?
GuideAI Health's Revenue of €0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on GuideAI Health and its competitors. GuideAI Health's current Revenue is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GuideAI Health stock overvalued right now?
GuideAI Health (FRA:ZN0) has a current Revenue of €0.00 Mil. The current Revenue is €0.00 Mil. GuideAI Health's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For GuideAI Health (FRA:ZN0), the current Revenue is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GuideAI Health Corp is a healthcare technology company using artificial intelligence to enable the early detection of vascular disease and support more precise treatment decisions. Its platform analyzes routine CT scans to identify peripheral vascular disease and other vascular conditions that are frequently missed or under-reported, generating structured, actionable reports for radiologists and treating clinicians. By surfacing disease earlier and matching findings to appropriate treatment pathways, it aims to improve patient outcomes while helping hospitals and radiology groups deliver more comprehensive vascular care. Its Platform Capabilities are AI-powered vascular imaging, Early detection of disease, subtle patterns and risk signals, Structured, consistent AI-generated, and Others.
16GF Score
Get the complete analysis for FRA:ZN0
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZN0 has been successfully added to your 
